Decade nine listed companies in pharmaceutical care in false advertising

on December 8, on suspicion of false advertising of the regulated Sally PuAi announcement said, the company received the Shanghai stock exchange information function and securities regulatory bureau, zhejiang province focused on function, focus on Sally PuAi thought whether to restart its products Sally PuAi thought eye drops the clinical effectiveness of test, etc.

map

incomplete statistics, over the past 10 years at least nine medicine, health products listed companies in & other; False advertising & throughout; The wave; Sally PuAi think advertisement cost relatively increased 2008 56 times

on December 8, on suspicion of false advertising of the regulated Sally PuAi announcement said, the company received the Shanghai stock exchange information function and securities regulatory bureau, zhejiang province focused on function, focus on Sally PuAi thought whether to restart its products Sally PuAi thought eye drops the clinical effectiveness of test, etc.

recently, Sally PuAi thought was & other Clove throughout the doctor &; In an article, “a year sells 750 million brainwashing god, please let the old man in China” question, think Sally PuAi think slogan has made consumers trust & other; Eye drops can cure cataract & throughout; , many consumers of complications, delayed treatment, and so on and so forth.

then Sally PuAi thought on December 6, the national food administration of drug safety requirements start clinical efficacy testing as soon as possible. On December 7, Sally PuAi shares were suspended.

reporter according to incomplete statistics, found that 10 years since 2007, at least nine of the listed pharmaceutical companies, medical treatment, health care products companies have been exposed for false advertising, and thus in a row, including love, ophthalmology, WoHua medicine, jiaotong university only, east treasure biological, nine typical pharma company, tonghua gold horse, Sally PuAi thought.

Sally PuAi thought was asked to start clinical effectiveness tests

on December 8 in the evening, Sally PuAi disclosure, the company received on the day of the Shanghai stock exchange “about Sally PuAi thought main product inquiry letter of parties on matters relating to the eye drops” zhejiang securities regulatory bureau and the SFC of the listed company regulatory attention “, the Shanghai stock exchange and securities regulatory bureau of zhejiang asked Sally PuAi think that clinical trials, drug approval, advertising, whether to have consumer complaints, suspected of bribery, and other issues.

the Shanghai asked Sally PuAi reply, early consistency is according to the quality of generic drugs and curative effect evaluation of the relevant provisions of the start-up company products Sally PuAi eye drops the clinical effectiveness of experiment. If yes, please disclose the current progress, subsequent specific arrangement and expected completion time, and explains the relevant test whether work form the preliminary results, whether of abnormal conditions; If not, please companies disclose the relevant work of the specific implementation plans and expected completion time.

Beijing news reporter learned that, as early as December 6, national food drug safety administration asked Sally PuAi thought in accordance with the pharmaceutical administration law of the People’s Republic of China and the quality of generic drugs and curative effect evaluation of the relevant provisions of the consistency, start the clinical effectiveness of testing as soon as possible, and the evaluation results reported in three years. At the same time, it also requires a kind of insect PuAi, strictly controlled drug use of words and the relevant provisions of the advertising laws and regulations to carry out comprehensive advertisement, is not in conformity with the provisions, immediately corrected, and reported to the local market regulator.

reporter noted that this year from Sally PuAi of the latest clinical research has been in the past nearly 20 years. Sally PuAi disclosed in the clarification announcement, the company’s eye drops are on the market in Italy in 1983, Sally PuAi cooperation and drug research institute of jiangsu province in 1991, started to work on the eye drops. In 1994, Sally PuAi eye drops for new drug approval documents of clinical research, 1998, 17 hospitals by the phase Ⅲ clinical tests have been carried out, at the end of the approval documents obtained the state food and drug turn formal production.

a Mr Geng, told reporters in the drug research and development of insect PuAi think if asked to completely restart the clinical trials of eye drops from at the end of the first clinical trials of phase 3 trials need for nearly three years of time, cost around 10 million, & other; Do not rule out they directly to a phase iii trial. Throughout the &;

9 years eye drops income increase 46 times, 3.72 yuan per yuan advertising produce revenue

Sally PuAi eye drops of revenue growth is faster. In 2008, its Sally PuAi eye drops income is 15.8147 million yuan, the product sales income over one hundred million yuan in 2011. This product business income is 752.5 million yuan in 2016. From 15.8147 million yuan to 752.5 million last year, the company products Sally PuAi think eye drops increased 46.62 times compared to the 9 years.

it is important to note that Sally PuAi think advertising the same period (2008-2016) from 4.5615 million yuan to 263 million yuan, 56.67 times year-on-year growth.

Mr. Geng told reporters that because of the pharmaceutical products have certain professional degrees, and some people are hard to through difficult terms to understand the role and function of a certain medicines or health products, in order to expand sales, medicine, health products and other products through advertising in the form of enlargement popularity is very common.

data show that Sally PuAi thought from 2014 to 2017, September 1 to the corresponding advertising costs 210 million yuan, 240 million yuan and 240 million yuan respectively, 220 million yuan, the company business income accounted for the proportion of 27%, 26%, 26.84%, 26%. Sally PuAi, from 2014 to 2017 in September 1 – business revenue is 766 million yuan and 922 million yuan respectively, 979 million yuan, 700 million yuan. To calculate, Sally PuAi every 2016 yuan advertising can bring up to $3.72.

and eye drops also became the most profitable product, Sally PuAi think Sally PuAi thought only eye drops in 2014, 2015, 2016, the resulting revenue is 500 million yuan and 660 million yuan respectively, 500 million yuan, profit margins are 95.57%, 95.3% and 95.57% respectively.

Leave a Reply

Your email address will not be published. Required fields are marked *